Related Experiment Video
Updated: Jun 20, 2026
10:31
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Obesity and chronic kidney disease
Eberhard Ritz1, Nadezda Koleganova
1Department of Internal Medicine, Ruperto Carola University, Heidelberg, Germany. Prof.E.Ritz@T-online.de
Seminars in Nephrology
|September 16, 2009
Abstract:
This article summarizes the current hypotheses that link visceral obesity and kidney malfunction and provides information on the epidemiology and renal pathology resulting from visceral obesity.
Insights
This article explores how visceral obesity, or abdominal fat, is linked to kidney malfunction. It details the epidemiology and kidney damage associated with this condition.
Area of Science:
- Nephrology
- Endocrinology
- Epidemiology
Background:
- Visceral obesity is a growing global health concern.
- Accumulation of abdominal fat is associated with various metabolic dysfunctions.
- Emerging evidence suggests a strong link between visceral obesity and kidney disease.
Purpose of the Study:
- To summarize current scientific hypotheses connecting visceral obesity and kidney malfunction.
- To provide an overview of the epidemiology of kidney disease in individuals with visceral obesity.
- To describe the renal pathology associated with visceral obesity.
Main Methods:
- Literature review of current scientific hypotheses.
- Analysis of epidemiological data on obesity and kidney disease.
- Summary of pathological findings in renal tissues.
Main Results:
- Several hypotheses link visceral fat accumulation to impaired kidney function.
- Epidemiological studies show a higher prevalence of kidney malfunction in obese populations.
- Renal pathology includes inflammation, fibrosis, and altered glomerular structure.
Conclusions:
- Visceral obesity is a significant risk factor for kidney malfunction.
- Understanding the link is crucial for developing targeted prevention and treatment strategies.
- Further research is needed to elucidate the precise mechanisms involved.
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...